Announced Tue, 19 May · 23:26 IST

Healthcare Global Enterprises Limited has informed the Exchange regarding Re-appointment of Mr Rajiv Maliwal as Non- Executive Independent Director of the company for a period of 5 years w.e.f. May 25, 2026 .

Management Changes View source PDF

HCG · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-2.7%1-day move
₹649.50
prior close
₹632.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+2.3+3.4+3.4+2.9-2.7+0.9+1.3+1.0+1.6-0.5-3.5-5.4+0.9
Up moveDown movePending
AI summary

HCG's board meeting on May 19, 2026 approved multiple key appointments. The headline item is the re-appointment of Rajiv Maliwal as Non-Executive Independent Director for a second 5-year term effective May 25, 2026, subject to shareholder approval. Maliwal is the founder of Sabre Partners and brings private equity and healthcare expertise. More significantly, Mr. Sanjeev Kumar (formerly Group CFO at InterGlobe Enterprises and Medanta, and a key figure in Global Health's IPO) has been appointed as the new Chief Financial Officer and KMP, effective May 25, 2026. Dr. Manish Mattoo, currently CEO serving as Interim CFO, will step down from the CFO role on that date, returning to his primary executive duties. Additionally, Mr. Ravi Gothwal (formerly with Medanta's investor relations team) has been appointed as AVP – Investor Relations (Senior Management Personnel) effective May 19, 2026. Mr. Vijay S. Shanbhag has been reappointed as Internal Auditor for one year from May 30, 2026.

Likely market impact

The new CFO appointment fills a critical vacancy and brings seasoned capital markets experience, which could boost investor confidence. The board-level continuity through Maliwal's re-appointment signals governance stability. The appointment of a dedicated Investor Relations head suggests increased focus on shareholder communication.